Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities

12 de maio de 2026 atualizado por: Amplexd Therapeutics, Inc.

A Phase II, Randomized, Double-blind, Placebo-Controlled, Proof of Concept Study to Assess the Safety and Efficacy of Dysplasix™ Intravaginally-Administered Suppositories in Patients With High-Risk Human Papillomavirus (Hr-HPV) as Determined by HPV Testing, and Accompanied by Either (1) Atypical Squamous Cells of Undetermined Significance (ASC-US) or (2) Low-Grade Squamous Intraepithelial Lesions (LSIL), as Determined by Cytology

The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women. It will also learn about the safety and tolerability of this investigational therapy. The main questions it aims to answer are:

  • Does the investigational therapy lead to regression of cervical lesions?
  • Does the investigational therapy help clear hr-HPV infection?
  • Do any adverse effects occur from using this medical product?

Researchers will compare the investigational therapy to a placebo (a look-alike substance that contains no active drug) to see if the investigational therapy works.

Participants will:

  • Be screened for hr-HPV, cervical abnormalities, and other conditions to be assessed for eligibility
  • Self-administer 15 doses of the investigational therapy or placebo as a vaginal suppository over 19 calendar days
  • Attend scheduled clinic visits for examinations, testing, and monitoring for a period of two months
  • Undergo assessments to evaluate cervical lesion status, hr-HPV infection, and safety outcomes
  • Keep a daily diary of investigational therapy use and associated information

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

AMP.2025.001 is a Phase II, Double-Blind, randomized, Placebo-Controlled, Proof-of-Concept study to assess the safety and efficacy of Dysplasix™ Intravaginal Suppositories in females with hr-HPV and one of the following: cytologically confirmed (1) Atypical Squamous Cells of Undetermined Significance (ASC-US) or (2) Low-Grade Squamous Intraepithelial Lesions (LSIL)

Participants must undergo both (1) HPV testing and (2) a liquid-based exfoliative cytology test.

If, at laboratory screening, high-risk HPV and either (1) ASC-US or (2) LSIL cytologic abnormalities are detected, participants will be eligible for inclusion. If high-grade SIL (HSIL) or glandular abnormalities (AGC-NOS, AGC-N, AIS) are detected, participants will be excluded.

Eligible participants with high-risk HPV and either (1) ASC-US or (2) LSIL cytology will be randomized in a 1:1 ratio to Dysplasix™ or a matching Placebo until participants who meet eligibility are enrolled. Suppositories (Dysplasix™) or placebo will be intravaginally self-administered once nightly for a fifteen (15) day course of therapy (3 cycles of 5 days followed by two days off between cycles) applied at night immediately before sleep, beginning shortly after the end of menses. Tolerability of the drug will be recorded in daily participant diaries and assessed at regularly scheduled clinical assessment visits.

Participants will undergo complete cervical screening, including hr-HPV testing and cytology 30 (+/- 14) days after completion of treatment in addition to adverse events assessments.

Adverse events are evaluated using Common Terminology Criteria for Adverse Events v5.0.

Tipo de estudo

Intervencional

Inscrição (Estimado)

45

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

  • Hong Kong
    • New Territories
      • Shatin, New Territories, Hong Kong
        • Recrutamento
        • Prince of Wales Hospital
        • Contato:
        • Investigador principal:
          • Kar Kei Yung, MBBS (HK), MRCOG, FHKCOG, FHKA

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

Participants must meet all the following criteria to be eligible to enroll in the study:

  1. Participants capable of giving informed consent
  2. Females, ages 18 to 65 years old at the time of signature of the informed consent form.
  3. Participants who are able to correctly self-administer the intravaginal suppositories
  4. One or more hr-HPV oncotypes as confirmed by HPV test
  5. Participants with ASCUS or LSIL abnormalities as confirmed by cytology
  6. Immune competent
  7. Participants of childbearing potential must have a negative pregnancy test at screening.
  8. Participants of childbearing potential must agree to use appropriate contraception or abstain from sexual intercourse for the duration of the study
  9. Participants must not have received a recent HPV vaccination and must abstain from HPV vaccination until the end of study

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded from the study:

  1. Presence of HSIL at screening cytology
  2. Evidence of glandular abnormalities (AGC/AIS) at screening cytology
  3. BMI below 16
  4. Pregnant or nursing females
  5. Evidence of vaginal/vulval comorbidities, specifically, common sexually transmitted or vaginal infections, and bloodborne pathogens
  6. Using a vaginal contraceptive ring
  7. History of irregular menstrual cycles or routine intermenstrual bleeding
  8. Active autoimmune disease
  9. Taking prohibited concomitant medications
  10. Concurrent malignancy except for non-melanoma skin lesions
  11. Active participation in another clinical trial involving therapeutic intervention (unless ending within 30 days of screening date)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Dysplasix™ Intravaginal Suppositories
Epigallocatechin gallate + Quinine Sulfate - Semisolid Intravaginal Suppository; 15 doses administered over the span of 3 x 5 consecutive nightly administration of investigational therapy, followed by a two day pause between cycles for a total of 15 doses administered over 19 calendar days. If menses occurs during treatment, investigational product use should be suspended until menses seizes and continued thereafter until 15 doses have been administered.
Medicamento: EGCG and Quinine Sulfate Vaginal Suppository

Epigallocatechin gallate + Quinine Sulfate - Dysplasix™ Semisolid Intravaginal suppository

15 doses administered over the span of 3 x 5 consecutive nightly administration of investigational therapy, followed by a two day pause between cycles for a total of 15 doses administered over 19 calendar days. If menses occurs during treatment, investigational product use should be suspended until menses seizes and continued thereafter until 15 doses have been administered.
Comparador de Placebo: Placebo Intravaginal Suppositories
Semisolid Intravaginal Suppository - 15 doses administered over the span of 3 x 5 consecutive nightly administration of investigational therapy, followed by a two day pause between cycles for a total of 15 doses administered over 19 calendar days. If menses occurs during treatment, investigational product use should be suspended until menses seizes and continued thereafter until 15 doses have been administered.
Outro: Placebo

Semisolid Intravaginal Suppository

15 doses administered over the span of 3 x 5 consecutive nightly administration of investigational therapy, followed by a two day pause between cycles for a total of 15 doses administered over 19 calendar days. If menses occurs during treatment, investigational product use should be suspended until menses seizes and continued thereafter until 15 doses have been administered.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
To determine and evaluate the safety and tolerability of Dysplasix™ intravaginal suppository therapy in females with hr-HPV and positive cytology for either ASCUS or LSIL.
Prazo: From enrollment until post-end of treatment follow up (Day 50 visit)
Number of participants with serious adverse events (SAEs) or dose-limiting toxicities (DLTs) related to the study intervention assessed using relevant Common Terminology Criteria for Adverse Events (CTCAE).
From enrollment until post-end of treatment follow up (Day 50 visit)
Regression of cervical cytology present at study entry
Prazo: From enrollment to post-end of treatment follow-up (Day 50 visit)
Participants whose baseline Atypical Cells of Undetermined Significance (ASCUS) or Low-Grade Squamous Intraepithelial Lesions (LSIL) regress to Normal for Intraepithelial Lesions or Malignancies (NILM), 30 days after completion of 15-day course of Dysplasix™ therapy (3 x 5-day cycles), as assessed by cytology
From enrollment to post-end of treatment follow-up (Day 50 visit)
Clearance of hr-HPV genotype present at study entry
Prazo: From enrollment to post-end of treatment follow-up (Day 50 visit)
Participants whose high-risk human papillomavirus (HPV) genotypes present at study entry become undetectable 30 days after completion of 15-day course of Dysplasix™ therapy (3 x 5-day cycles), as assessed by HPV testing
From enrollment to post-end of treatment follow-up (Day 50 visit)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Amplexd Therapeutics, Inc.

Colaboradores

Chinese University of Hong Kong
Prince of Wales Hospital, Shatin, Hong Kong

Investigadores

  • Investigador principal: Kar Kei Yung, MBBS (HK), MRCOG, FHKCOG, FHKA, Prince of Wales Hospital, Chinese University of Hong Kong

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

30 de abril de 2026

Conclusão Primária (Estimado)

27 de dezembro de 2026

Conclusão do estudo (Estimado)

27 de janeiro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

1 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de maio de 2026

Primeira postagem (Real)

7 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

14 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de maio de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • AMP.2025.001
  • 200922 (Outro identificador: Hong Kong Department of Health (Pharmacy and Poisons Ordinance))
  • 2025.300 (Outro identificador: Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research and Ethics Committee (CREC))

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

The sponsor is in the process of finalizing an IPD sharing policy and governance framework.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever